← FDA DRUG APPROVALS

FDA NDA · NDA021677

ALIMTA

Sponsor: LILLY

APPLICATION
NDA021677
TYPE
NDA
ORIGINAL APPROVAL
2004-08-19
LATEST ACTION
2004-08-19
ROUTE
INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Prescription

Products

ALIMTAPrescription
PEMETREXED 500MG · INJECTABLE · INJECTION

Approval history

2004-08-19Type 9 - New Indication Submitted as Distinct NDA, Consolidated with Original NDA after Approval · Original · standardLabelAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →